Objective: To evaluate the efficacy and safety of percutaneous nephrolithotomy (PCNL) in the treatment of congenital autosomal dominant polycystic kidney disease (ADPKD) with renal calculi. Methods: A total of 11 cases of ADPKD with renal calculi were retrospectively studied. All cases were treated by PCNL and clinical parameters such as age, sex, stone burden, operation time, blood loss, complications and perioperative serum creatinine levels were collected and analyzed. All patients were routinely followed up for 36 months postoperatively and the efficacy and safety of PCNL in the management of ADPKD with renal calculi were assessed. Results: All procedures were successful without conversion to open surgery. The mean stone burden was 3.4 ± 0.7 cm (range 2.5-4.6 cm). The overall stone clearance rate was 81.8% (9/11). Two patients received extracorporeal shock wave lithotripsy postoperatively because of residual calculi. The mean operation time was 77 ± 23.5 min (range 45-128 min) and the mean blood loss was 147 ± 56 ml (range 80-260 ml). The mean preoperative serum creatinine level was 15.13 ± 3.30 mg/dl (range 9.90-20.14 mg/dl) and the mean postoperative serum creatinine level was 14.28 ± 2.24 mg/dl (range 10.76-17.28 mg/dl). Four cases had fever postoperatively (36.4%). Three patients had hemorrhage and two patients received blood transfusion. No patient had peripheral viscera injury. Statistical comparison showed that PCNL had no impact on perioperative renal function (p > 0.05). Conclusions: In spite of anatomical deformation and impairment of renal function, PCNL is an effective and safe procedure in managing ADPKD with renal calculi.

Keywords:
Autosomal dominant polycystic kidney disease, Renal calculi, Percutaneous nephrolithotomy
1.
Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT: Epidemiology of adult polycystic kidney disease. Am J Kidney Dis 1983;2:630-639.
2.
Torres VE, Holley KE, Offord KP: General features of autosomal dominant polycystic kidney disease; in Grantham J, Gardner K (eds): Problems in Diagnosis and Treatment of Polycystic Kidney Disease. Kansas City, PKD Foundation, 1985, pp 49-69.
3.
King BF, Reed JE, Bergstralh EJ, Sheedy PF 2nd, Torres VE: Qualification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11:1505-1511.
4.
Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW: Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002;39:1127-1134.
5.
Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Magnetic resonance measurement of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007;2:112-120.
6.
Torres VE, Erickson SB, Smith LH, Wilson DM, Hattery RR, Segura JW: Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993;22:513-519.
7.
Al-Tawheed AR, Al-Awadi KA, Kehinde EO, Abdul-Halim H, Hanafi AM, Ali Y: Treatment of calculi in kidneys with congenital anomalies: an assessment of the efficacy of lithotripsy. Urol Res 2006;34:291-298.
8.
Baishya R, Dhawan DR, Kurien A, Ganpule A, Sabnis RB, Desai MR: Management of nephrolithiasis in autosomal dominant polycystic kidney disease - a single center experience. Urol Ann 2012;4:29-33.
9.
Srivastava A, Bansal R, Srivastava A, Chaturvedi S, Ranjan P, Ansari MS, Yadav A, Kapoor R: Percutaneous nephrolithotomy in polycystic kidney disease: is it safe and effective? Int Urol Nephrol 2012;44:725-730.
10.
Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-1301.
11.
Deliveliotis C, Argiropoulos V, Varkarakis J, Albanis S, Skolarikos A: Extracorporeal shock wave lithotripsy produces a lower stone-free rate in patients with stones and renal cysts. Int J Urol 2002;9:11-14.
12.
Umbreit EC, Childs MA, Patterson DE, Torres VE, LeRoy AJ, Gettman MT: Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease. J Urol 2010;183:183-187.
13.
Al-Kandari AM, Shoma AM, Eraky I, El-Kenawy MR, Al-Eezi H, El-Kappany HA: Percutaneous nephrolithotomy for management of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease. Urology 2009;74:273-277.
14.
Singla M, Srivastava A, Kapoor R, Gupta N, Ansari MS, Dubey D, Kumar A: Aggressive approach to staghorn calculi - safety and efficacy of multiple tracts percutaneous nephrolithotomy. Urology 2008;71:1039-1042.
15.
Jhuang YB, Chung HM, Wu TM, Tsai YC: Treating large renal stones in a case of autosomal dominant polycystic kidney disease by flexible ureteroscopy with holmium laser lithotripsy. JTUA 2009;20:140-142.
16.
Yili L, Yongzhi L, Ning L, Dongwei X, Chunlai L, Suomin L, Ping W: Flexible ureteroscopy and holmium laser lithotripsy for treatment of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease. Urol Res 2012;40:87-91.
17.
Takazawa R, Kitayama S, Tsujii T: Successful outcome of flexible ureteroscopy with holmium laser lithotripsy for renal stones 2 cm or greater. Int J Urol 2012;19:264-267.
18.
Ng CS, Yost A, Streem SB: Nephrolithiasis associated with autosomal dominant polycystic kidney disease: contemporary urological management. J Urol 2000;163:726-729.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.